Metal-polyphenol polymer modified polydopamine for chemo-photothermal therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Combined chemotherapy and photothermal therapy (PTT) presents a promising strategy to enhance cancer treatment efficacy.
• Developing multifunctional nanoparticles is crucial for targeted drug delivery and synergistic therapeutic effects.

Purpose of the Study:

• To develop and evaluate a novel multifunctional nanoparticle (PTX@mPDA@Fe-GA) for synergistic chemotherapy and PTT in lung cancer.
• To investigate the pH- and thermal-dual responsive drug release characteristics of the nanoparticles.
• To assess the in vitro and in vivo anti-cancer efficacy and biocompatibility of the developed nanocarrier.

Main Methods:

• Fabrication of mesoporous polydopamine (mPDA) nanoparticles coated with Fe-gallic acid (Fe-GA) and loaded with paclitaxel (PTX).
• Characterization of nanoparticle properties, including photothermal conversion ability, drug release kinetics (pH and thermal responsiveness), biocompatibility, and hemolysis rate.
• Evaluation of in vitro cytotoxicity against A549 lung cancer cells and in vivo anti-tumor efficacy in a mouse xenograft model.

Main Results:

• The PTX@mPDA@Fe-GA nanoparticles exhibited pH- and thermal-dual responsive release of paclitaxel.
• Both mPDA and Fe-GA components demonstrated significant photothermal conversion efficiency.
• The nanoparticles showed excellent biocompatibility with a low hemolysis rate.
• PTX-loaded nanoparticles effectively inhibited A549 lung cancer cell proliferation in vitro and suppressed subcutaneous tumor growth in vivo.

Conclusions:

• The developed multifunctional nanoparticles successfully integrate chemotherapy and photothermal therapy for enhanced lung cancer treatment.
• PTX@mPDA@Fe-GA nanoparticles offer a promising platform for targeted drug delivery and synergistic cancer therapy.
• This approach provides innovative therapeutic strategies for combating lung cancer.